Care Management Solutions Market Analysis, Trends and Demand,

Care Management Solutions Market

The growth of global care management solutions market is led by growing geriatric population, increasing demand for quality of care and increasing government initiatives to promote patient-centric care, increasing prevalence of chronic diseases, advancing IT and big data capabilities and growing medical tourism. Initiatives to move the burden of threat from healthcare payers to providers and need to reduce healthcare cost are further expected to boost the demand of these solutions. The fastest increase in demand of care management solutions during the forecast period is expected to be witnessed in chronic care management segment, due to increasing demand of improving quality of care and save time for providers. Based on component, software segment leads the global market in terms of size, due to technological advancement in IT solution, growth of cloud computing and increased access of internet across the globe.

Explore Report at: https://www.psmarketresearch.com/market-analysis/care-management-solutions-market

Increasing prevalence of chronic diseases is driving the growth of the global care management solutions market due to increasing demand for quality of care. The prevalence of chronic diseases, such as heart disease, cancer, stroke and respiratory disease, are increasing due to the alteration in lifestyle and lack of access to preventive care. According to the Centers for Disease Control and Prevention (CDC), approximately 117 million people in the U.S. had one or more chronic health conditions in 2012.

Care management solution is an integrated healthcare solution that offers products and services to improve quality of care of patients. It identifies the need of care, manage care, monitor results and outcomes, assess patient’s needs, and establish the appropriate care plan to support their needs. It combines analytics, data integration, and coordination of care capabilities into a single solution.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/care-management-solutions-market/report-sample

The key players operating in the global market are Allscripts Healthcare solutions Inc., Cerner Corporation, Epic Corporation, Inc., Wellentive Inc., I2I System Inc, and IBM Corporation.

Multiple Myeloma Therapeutics Pipeline – Patent, Collaboration and Other Developments

Multiple Myeloma (MM) Therapeutics Pipeline

The multiple myeloma therapeutics pipeline is expected to witness considerable growth in the coming year due to high prevalence of the disease. The growth of multiple myeloma therapeutics pipeline is assisted by targeted therapy and new effective treatment. Also, increased awareness among the population about the various cancer treatments has further fueled the growth of the therapeutics pipeline. Increasing healthcare expenditure and technological advancements are supporting the growth of the therapeutics pipeline for multiple myeloma. An increasing demand for safe and effective medications is also driving the growth of the multiple myeloma therapeutics pipeline. Many government initiatives such as increased funding, designations and grants for speeding up the drug development process has also supported the growth of the therapeutics pipeline.

Explore Report at: https://www.psmarketresearch.com/market-analysis/multiple-myeloma-therapeutics-pipeline-analysis

The National Cancer Institute, which is a part of the U.S. National Institutes of Health, defines multiple myeloma as a cancer that is formed by malignant plasma cells. Normal plasma cells are found in the bone marrow as an important part of the immune system. The immune system is made up of several types of cells that work together to fight infections and other diseases. Lymphocytes (lymph cells) are the main cell types of the human immune system and the major types of lymphocytes are T cells and B cells. When B cells respond to an infection, they mature and change into plasma cells. Plasma cells make the antibodies (also known as immunoglobulins) that help the body attack and kill germs. Lymphocytes are present in many areas of the body, such as lymph nodes, bone marrow, intestines, and the bloodstream. Plasma cells, however, are mainly found in the bone marrow. Bone marrow is the soft tissue found inside some hollow bones. In addition to plasma cells, the bone marrow has those cells that make the different normal blood cells.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/multiple-myeloma-therapeutics-pipeline-analysis/toc-sample

Some of the companies having a pipeline of myeloma therapeutics include Celgene Corporation, Bristol-Myers Squibb, Abbvie, Inc., Novartis AG, F. Hoffman La Roche AG, Amgen, Inc., Karyopharm Therapeutics, Inc., Array BioPharma, and Takeda Pharmaceutical Company Limited.

Cluster Headache Therapeutics Pipeline Analysis 2017 – Collaboration and Other Developments

Cluster Headache Therapeutics Pipeline Analysis

Rapidly increasing pace of life, change in lifestyle, higher stress levels, etc., are few of the major factors to which the increasing prevalence of cluster headache scan be attributed. Further, unhealthy dietary intake, smoking, alcoholconsumption and growing levels of pollutionare few other factors which are expected to fuel the incidence of cluster headache problem. The Therapeutic pipeline of cluster headache is expected to grow in future with the participation of various pharmaceutical companies that are focusing on developing novel drugs for curing the problem of cluster headache. As per WHO, problem of cluster headache is more common in men, as compared to women, and mostly in people in the age group of 20 to 40 years. According to a recently published NCBI paper, one of every 1,000 adults in the U.S. experiences the problem of cluster headache. In spite of the problem of cluster headache being very common, it has mostly been under-recognized and has been overlooked.

Explore Report at: https://www.psmarketresearch.com/market-analysis/cluster-headache-therapeutics-pipeline-analysis

Cluster headache, also called ashistamine headache, is a primary headachedisorder of the nervous system, and is a headache of constant nature, experienced over a prolonged period of time, occurring mostly at night during sleep. According to the studies conducted by International Headache society (IHS), during cluster headache the patient experiences very severe pain, which occurs for duration of 15 to 180 minutes, once a day. Lacrimation, facial sweating, eyelid edema, restlessness, runny nose, rhinorrhea, ptosis, one-sided pain, nasal congestion, miosis & conjunctivitis, are few of the symptoms ofdiagnosing cluster headache.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/cluster-headache-therapeutics-pipeline-analysis/toc-sample

Some of the companies having a pipeline of cluster headache therapeutics include Eliy-lilly& Company, Teva pharmaceuticals industries Ltd, Winston laboratories,Gilead Sciences, Inc., Galapagos NV, Astellas Pharma, Abbvie, Inc., Bexalta US, Inc., Optimer pharmaceutical LLC.

Asthma Therapeutics Pipeline Analysis 2017

Asthma Therapeutics Pipeline Analysis

The pipeline for asthma therapeutics is expected to experience a positive trend in the future, the increase is mainly attributable to decreasing air quality. The prevalence of asthma is increasing globally due to the factors including environmental factors, genetic factors, air pollution, less physical activity and smoking. These factors contribute immensely in driving the pipeline analysis for asthma. According to World Health Organization, around 235 million people suffered from asthma, in 2013. Asthma related deaths occurs more commonly in low and lower middle income countries. Asthma is a very common disease and the treatment options available for the same are expensive. It has been also notes that the disease is more prevalent in women as compared to men.

Explore Report at: https://www.psmarketresearch.com/market-analysis/asthma-therapeutics-pipeline-analysis

Asthma is a chronic disease that involves inflammation of bronchial tubes. Bronchial tubes allow air to pass through the lungs and when the lungs get inflamed muscles tend to become stiff, resulting in various symptoms that might be experienced by the patient. The inflammation of bronchial tubes affects the air passage which results in the occurrence of symptoms including breath shortening, wheezing, coughing and chest congestion. These symptoms are usually very active during physical activities such as exercising, walking and running. People with family history of asthma have more chances to develop asthma. There is no cure of asthma, but various treatment options can help to improve the quality of life of patient. Along with the common symptoms of asthma, pattern of symptoms occurrence is also important during diagnosis. Patterns usually include during exercise, during particular season and morning or night. Asthma can be diagnosed by analysing the patient’s family history and certain breathing tests such as spirometry. Asthma cannot be cured but the disease can be dealt with its proper management. . There are certain marketed drugs that are used in the form of inhalation for managing asthma include inhaled corticosteroids, budesonide, mometasone, ciclesonide, flunisolide and beclomethasone.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/asthma-therapeutics-pipeline-analysis/toc-sample

Some of the companies having a pipeline of asthma therapeutics include Regeneron Pharmaceuticals, Inc., Novartis AG, Chiesi Farmaceutici S.p.A., GlaxoSmithKline plc, AstraZeneca plc, Merck Sharp & Dohme Corp., Mundipharma Research Limited, Actavis Inc., Sanofi, AbbVie, Inc., Boehringer Ingelheim GmbH, Genentech, Inc., Rhizen Pharmaceuticals SA.

Sjögren’s Syndrome Therapeutics Pipeline Analysis, 2017 – Designation, Collaboration and Other Developments

Sjögren_s Syndrome Therapeutics Pipeline

The study analyzed that Sjögren’s syndrome pipeline comprises of approximately 42 drug candidates in different stages of development. Sjögren’s syndrome is a chronic inflammatory disease, which leads to infiltration of lacrimal and salivary glands. It is mostly associated with sicca symptoms, which include dry eyes (xeropthalmia) and dry mouth (xerostomia). It is also associated with other autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis. The treatment approaches for this disease mostly include monoclonal antibodies and small molecules, which are being developed to target and reduce the inflammatory mediators. Clinical presentation can vary considerably from relatively mild sicca symptoms, fatigue and arthralgia to severe systemic symptoms such as glomerulonephritis, vasculitis and a host of neurological manifestations.

Browse Report Description at: https://www.psmarketresearch.com/market-analysis/sjogrens-syndrome-therapeutics-pipeline-analysis

The positive results of the drug candidates are speeding up the drug development process for Sjögren’s syndrome. In August 2016, Aldeyra Therapeutics, Inc. presented the positive Phase II results of NS2, a 1% dermatologic cream under Phase II stage of development for Sjögren’s syndrome. Six of six (100%) subjects treated with NS2 improved over the course of therapy as assessed by central review, and the improvement was greater than that observed among vehicle-treated patients (p < 0.05).

The research found that different companies have collaborated for the development of Sjögren’s syndrome.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/sjogrens-syndrome-therapeutics-pipeline-analysis/report-sample

Some of the key players developing drugs for Sjögren’s syndrome include Kissei Pharmaceutical Co., Ltd., UCB Group, Bristol-Myers Squibb Company and others.

Systemic Lupus Erythematosus Pipeline Analysis 2017

The study analyzed that the systemic lupus erythematosus pipeline comprises of 57 drug candidates in different stages of development. Systemic lupus erythematosus is a type of lupus in which the immune system damages its own tissues. The disease affects many parts of the body including skin, joints, lungs, brain, blood vessels and kidneys. The systemic lupus erythematosus is caused by impaired immune system due to which the immune system attacks its own tissues and can cause widespread inflammation and tissue damage in the affected organs. Some of the common symptoms of systemic lupus erythematosus include oral ulcers, sun sensitivity, heart problems, kidney problems, psychosis, lung problems, arthritis, seizures, fevers, skin rashes, fatigue, swelling and pain in the joints. Systemic lupus erythematosus is being treated using a combination approach as number of organs are involved. Therefore, various combination therapies are being used to improve quality of life of the patients. Also, combining novel drugs against different organs as well as combination of drugs with biological and biochemical agents may further enhance the treatment quality.

Explore Report Description at: https://www.psmarketresearch.com/market-analysis/systemic-lupus-erythematosus-pipeline-analysis

Seattle Genetics, Inc. is using antibody-drug conjugate (ADC) technology platform for the development of Brentuximab vedotin for the treatment of systemic lupus erythematosus. The technology platform employs a monoclonal antibody specific for a tumor-associated antigen, plus synthetic cytotoxic (cell-killing) agents connected by stable linker systems designed to securely bind the cytotoxic agent to the antibody and then release the agent within the targeted cell.

The research also found that various companies have collaborated for the development of systemic lupus erythematosus pipeline.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/systemic-lupus-erythematosus-pipeline-analysis/report-sample

Some of the key players developing drugs for systemic lupus erythematosus include Anthera Pharmaceuticals, Inc., Genentech, Inc., Merck KGaA and others.

Pharmaceutical Membrane Technology Market Opportunities and Demand Forecast to 2023

Pharmaceutical Membrane Technology Market

Membrane technology is also widely used in improving water quality by removing particles, natural organic matter, pathogens (viruses and bacteria), emerging substances, and other dissolved matter from drinking water. Furthermore, membrane technology is used for the improvement of biological stability of drinking water in the distribution network. Water companies are legally forced to enhance the quality of drinking water in order to fulfill public health requirements. The enhancement is achieved by improving water quality and by operating water treatment processes more cost-efficiently with the help of membrane technology.

For more information visit: https://www.psmarketresearch.com/market-analysis/pharmaceutical-membrane-technology-market

Global pharmaceutical membrane technology market can be categorized on the basis of technology as ultrafiltration, reverse osmosis, microfiltration, chromatography and, nano filtration. Some of the major trends in the membrane technology market are product innovation and product portfolio expansion. The global membrane technology market is also going through large number of mergers, acquisitions and collaborations in recent years.

North America is the largest market for pharmaceutical membrane technology, owing to high concentration of pharmaceutical and biopharmaceutical manufacturing companies in the region. In Europe, many organizations, associations and societies are involved in development and implementation of membrane technology in pharmaceutical, biopharmaceutical and life sciences industries. However, Asia-Pacific is the fastest growing market for pharmaceutical membrane technology due to continuous development in pharmaceutical and biopharmaceutical industries. Additionally, increasing healthcare awareness, growing incidence of life style diseases, large population base and increasing government healthcare spending in developing countries of Asia-Pacific is driving the market for pharmaceutical membrane technology.

Request for Table of Content: https://www.psmarketresearch.com/market-analysis/Pharmaceutical-Membrane-Technology-Market/toc-sample

Some of the major competitors in global pharmaceutical membrane technology market are Amazon Filters Ltd., 3M Company, Pall Corporation, Advantec MFS Inc., Sartorius AG, GE Healthcare Life Sciences, Novasep, Merck Millipore (EMD Millipore), Koch Membrane Systems Inc., and TriSep Corporation.

Opioid-Induced Constipation Market Forecast to 2023

Opioid-Induced Constipation Market

Opioids are directed to the patients suffering from the acute and chronic non-cancer pain. The opioids have numerous adverse intestinal effects, such as opioid-induced constipation. The opioids also affect the discharge of digestive enzymes that can sometime cause partial gastro paresis. Some of the most familiar symptoms of opioid-induced constipation includes, hard and dry stools, swelling, painful defecation, distention and protruded abdomen, tiredness, and loss of hunger. Some of the most common opioid-induced constipation therapy is the use of targeted therapies, OTC and off-label drugs and changing lifestyle.

To Know More Visit: https://www.psmarketresearch.com/market-analysis/opioid-induced-constipation-market

Based on the drug action mechanism the global opioid induced constipation market can be segmented as: peripherally acting mu-opioid receptor antagonist, locally acting chloride channel activator, and others. Based on the administration route of drugs the global opioid-induced constipation market can be segmented into two broad categories: oral and parental.

Lack of awareness about the opioid-induced constipation in patients, and the doctors are one of the dominant causes of off-label and OIC medications as majorly used treatment methods. However, the efficiency of these drugs is only the half of some of the other therapies. The entrance of superficially acting mu-opioid receptor rivals such as Movantikv or Moventig are driving the opioid-induced constipation market. Movantikv or Moventig drug targets only the fundamental reason of opioid-induced constipation without affecting the effect of the opioid drugs.

Complicated treatment technology and lack of awareness regarding the upcoming treatment technology are some of the most dominant restrain for the opioid-induced constipation market. Cost effective research and development (R&D) in the development of new and effective treatment technology in the opioid-induced constipation market is one of the recent trend in the industry.

Request for Table of Content: https://www.psmarketresearch.com/market-analysis/Opioid-Induced-Constipation-Market/toc-sample

Some of the major players operating in the global opioid-induced constipation market include, AstraZeneca plc, Valeant Pharmaceuticals International Inc., Takeda Pharmaceutical Co. Ltd., Salix Pharmaceuticals, Ltd., Progenics Pharmaceuticals, Inc., Abbott Laborites, and Bayer AG among others.

Disinfectors Market Size, Share, Development and Demand Forecast to 2023

Disinfectors Market

Owing to the fact that cleaning and sanitation are vital for safety in the healthcare industries, the global market for disinfectants is driven by increased focus on hygiene and growing concerns over the spread of infectious diseases both at home and in public places. Rising demands in the food, beverage and healthcare industries is driving the global disinfectors market. Disinfectant chemicals are also becoming more common as an ingredient in various conventional and industrial cleaning products.

Explore Report at: https://www.psmarketresearch.com/market-analysis/disinfectors-market

Disinfectors are used for destroying pathogens for controlling infection.
Disinfection is an essential procedure that is performed for infection control in households and in healthcare facilities such as clinics, hospitals, elder care institutes and laboratories, using disinfectors and other infection control equipment such as sterilizers. Disinfectors are used to disinfect various medical instruments such as bedpans, surgical instruments, urine bottles and endoscopes. Disinfection is the process of destroying pathogenic organisms or rendering them inert. Hence, it ensures the hygiene condition of medical appliances that are used while providing medical services to people by healthcare workers.

The global disinfectant market can be categorized on the basis of disinfectors by product type, and disinfectors by applications. Based on disinfectors by product type, the global market for disinfectors is divided into washer, flusher and endoscope reprocessor. The washer is further divided into a single chamber (single door and double door) and multi chamber. On the basis of application, the global disinfectors market is classified into elder care, hospitals and clinics, and pharmaceuticals and life sciences.

Request for table of Content at: https://www.psmarketresearch.com/market-analysis/disinfectors-market/toc-sample

The rise in number of healthcare infrastructure in developing countries is one of the major trends in the disinfectors market. The large population in developing countries has opened up a large patient pool which eventually gives a rise in disposable income. The favorable economic conditions in most of the developing countries are propelling the infrastructural growth by establishing more medical care facilities and hospitals. Liquid products and aerosol are the most commonly used surface decontaminators, though a significant number of hospitals are employing UV disinfection systems as an surplus measure. Hence, another trend in the disinfectors market is the use of ultraviolet (UV) disinfectors as UV radiation inactivates micro-organisms by destroying the nucleic acids in viruses and bacteria.

Owing to the rise in number of chronic diseases, epidemic diseases such as H1N1 and aging population, North America dominates the disinfectors market followed by Europe.. Some of the major competitors in the global disinfectors market are Advanced Sterilization Products Division Ethicon US, LLC, Getinge AB, OLYMPUS CORPORATION and STERIS Corporation. Other prominent competitors in the market include ACTAVIS, American Biotech Labs, LLC, Amrep Inc, CareFusion Corporation, CCP Industries , Bio-Cide International, Inc., BIOTECHMEDICS US., Cantel Medical, Colgate-Palmolive Company., Swisher International, Inc., Diversey Inc.and many more.

 

Hypodermic Needle Market Analysis, Size, Development and Forecast to 2022

Hypodermic Needle Market

The global hypodermic needles market is expected to grow at a CAGR of 7.4% during 2016 – 2022. The growth of the global market is largely driven by the high demand for vaccines and increasing compliance of safety needles. High prevalence of needle stick injuries during drug administration is a key concern for healthcare providers across the globe. Improper disposal of syringe and needles is creating the demand for advanced safety mechanisms in hypodermic needles. Globally, approximately 16 billion injections are administered every year as per the World Health Organization (WHO); however, all the syringes and needles are not properly disposed of. Therefore, several benefits of safety needles such as ease of use during injection and safe delivery of drug or medication are increasing their popularity among healthcare providers.

Explore Report with Detailed TOC on “Global Hypodermic Needle Market” at: https://www.psmarketresearch.com/market-analysis/hypodermic-needles-market

Healthcare providers along with patients are getting aware about safety in drug delivery through syringes. This has created huge traction in the global market for developing advanced safety hypodermic needles with automatic features. Some of the other factors driving the growth of the global market include increasing prevalence of chronic and lifestyle associated diseases, and geriatric population. Increasing adoption of hypodermic needles in emerging economies is expected to create ample growth opportunities for the global market. However, alternative drug delivery method and high cost of hypodermic needles are the key barriers for the growth of the global market.

North America led the global hypodermic needle market in terms of size in 2015, owing to the increasing awareness of safe injectable technology, and increasing prevalence of chronic and lifestyle associated diseases. The U.S. contributed largest revenue to the North American as well as the global hypodermic needle market. The country is expected to remain the largest market for hypodermic needle globally during the forecast period.

Request For Sample Pages: https://www.psmarketresearch.com/market-analysis/hypodermic-needles-market/report-sample

Some of the players operating in the global market include Vygon S.A., Catalent, Inc., Terumo Corporation, Retractable Technologies, Inc., Connecticut Hypodermics, Inc., MedPro Safety Products Inc., B. Braun Melsungen AG, Albert David Ltd., Becton, Dickinson and Company, and Medtronic plc.